Document:

Exhibit 10.17

FORM OF SERIES A WARRANT

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, (B) AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (C) REASONABLE ASSURANCE HAVING BEEN PROVIDED TO THE COMPANY THAT SUCH OFFER, SALE, ASSIGNMENT OR TRANSFER IS BEING MADE PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.  NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

VERILINK CORPORATION

SERIES A WARRANT TO PURCHASE COMMON STOCK

Warrant No.: A-__
 Number of Shares of Common Stock: ______
 Date of Issuance: March 21, 2005  (“Issuance Date”)

                    Verilink Corporation, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, __________________, the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), at any time or times on or after the Issuance Date but not after 11:59 p.m., New York Time, on the Expiration Date (as defined below), _______ fully paid nonassessable shares of Common Stock (as defined below)(the
“Warrant Shares”).  Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 15.  

                    This Warrant amends, supplements, modifies and completely restates the Warrant, dated as of March 21, 2005 (the “Existing Warrant”), issued by the Company to the Holder, but shall not, except as specifically amended hereby, constitute a release, satisfaction or novation of any of the obligations under any Transaction Document (as defined in the Securities Purchase Agreement, dated as of March 20, 2005 (the “Subscription Date”), by and among the Company and the investors (the “Buyers”) referred to therein (the “Existing Securities Purchase Agreement”) as amended by the Consent, Amendment and Exchange Agreement, dated March 9, 2006

(the “Exchange Agreement”), by and among the Company and the Holder (as amended, the “Securities Purchase Agreement”).  This Warrant is one of the series of Replacement Warrants (as defined in the Exchange Agreement) to purchase Common Stock (the “Replacement SPA Warrants”, and together with the Additional Warrants (as defined in the Exchange Agreement), the “SPA Warrants”) issued pursuant to the Exchange Agreement and the other Consent, Amendment and Exchange Agreements, each dated as of March 9, 2006, by and among the Company and each of the other Buyers (collectively with the Exchange Agreement, the “Exchange Agreements”).

                    1.          EXERCISE OF WARRANT.

                                        (a)          Mechanics of Exercise.  Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by the Holder on any day on or after September 21, 2005 in whole or in part, by (i) delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant, (ii) (A) payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”)
in cash or wire transfer of immediately available funds or (B) by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)).  The Holder shall not be required to deliver the original Warrant in order to effect the exercise hereunder.  Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.  On or before the first Business Day following the date on which the Company has received each of the Exercise Notice and the Aggregate Exercise Price (or notice of a Cashless Exercise) (the “Exercise Delivery Documents”), the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of the Exercise Delivery Documents to the Holder and the Company’s transfer agent (the “Transfer
Agent”).  On or before the third Business Day following the date on which the Company has received all of the Exercise Delivery Documents (the “Share Delivery Date”), the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program and such action is not prohibited by applicable law or regulation or any applicable policy of DTC, upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission system, or (Y) if the foregoing shall not apply, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common
Stock to which the Holder is entitled pursuant to such exercise.  Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares.  If this Warrant is delivered to the Company in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than five Business Days after the Share Delivery Date and at its own expense, issue a new Warrant (in

- 2 -

accordance with Section 7(d)) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.  No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number.  The Company shall pay any and all taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant; provided that the Company shall not be required to pay any tax that may be payable in respect of any issuance and delivery of Warrant Shares to any Person other than the Holder or with respect to any income tax due by the Holder with respect to such Warrant Shares.

                                        (b)          Exercise Price.  For purposes of this Warrant, “Exercise Price” means $0.93, subject to adjustment as provided herein.

                                        (c)          Company’s Failure to Timely Deliver Securities.  If the Company shall fail for any reason or for no reason to issue to the Holder on or before the Share Delivery Date, a certificate for the number of shares of Common Stock to which the Holder is entitled and register such shares of Common Stock on the Company’s share register or to credit the Holder’s balance account with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder’s exercise of this Warrant, then, in addition to all other remedies available to the Holder, the Company shall pay in cash to the Holder on each day after such Share Delivery
Date that the issuance of such shares of Common Stock is not timely effected an amount equal to 2.0% of the product of (A) the sum of the number of shares of Common Stock not issued to the Holder on a timely basis and to which the Holder is entitled and (B) the Closing Sale Price of the shares of Common Stock on the trading day immediately preceding the last possible date which the Company could have issued such shares of Common Stock to the Holder without violating Section 1(a).  In addition to the foregoing, if on or before the Share Delivery Date the Company shall fail to issue and deliver a certificate to the Holder and register such shares of Common Stock on the Company’s share register or credit the Holder’s balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon such holder’s exercise hereunder, and if on or after such Share Delivery Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to
deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a “Buy-In”), then the Company shall, within three Business Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such certificate (and to issue such shares of Common Stock) shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such shares of Common Stock and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the Closing Bid Price on the date of exercise.

                                        (d)          Cashless Exercise.  Notwithstanding anything contained herein to the contrary, if a Registration Statement (as defined in the Registration Rights Agreement) covering the Warrant Shares that are the subject of the Exercise Notice (the “Unavailable Warrant Shares”) is not available for the resale of such Unavailable Warrant Shares, the Holder may, in

- 3 -

its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common Stock determined according to the following formula (a “Cashless Exercise”):

                                        Net Number = (A x B) - (A x C)

                                                                             B

                                        For purposes of the foregoing formula:

                    A= the total number of shares with respect to which this Warrant is then being exercised.

                    B= the Closing Sale Price of the shares of Common Stock (as reported by Bloomberg) on the date immediately preceding the date of the Exercise Notice.

                    C= the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

                                        (e)          Disputes.  In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12.

                                        (f)          Limitations on Exercises.

	
  
 
  	
  
          (i)          Beneficial   Ownership.  Other than in connection   with a Fundamental Transaction pursuant to Section 4(a), the Company shall   not effect the exercise of this Warrant, and the Holder shall not have the   right to exercise this Warrant, to the extent that after giving effect to   such exercise, such Person (together with such Person’s affiliates) would   beneficially own in excess of 4.99% (the “Maximum   Percentage”) of the shares of Common Stock outstanding immediately   after giving effect to such exercise.    For purposes of the foregoing sentence, the aggregate number of shares   of Common Stock beneficially owned by such Person and its affiliates shall   include the number of shares of Common Stock issuable upon exercise of this   Warrant with respect to which the determination of such sentence is
being   made, but shall exclude shares of Common Stock which would be issuable upon   (i) exercise of the remaining, unexercised portion of this Warrant   beneficially owned by such Person and its affiliates and (ii) exercise or   conversion of the unexercised or unconverted portion of any other securities   of the Company beneficially owned by such Person and its affiliates   (including, without limitation, any
  

- 4 -

	
  
 
  	
  
convertible   notes or convertible preferred stock or warrants) subject to a limitation on   conversion or exercise analogous to the limitation contained herein.  Except as set forth in the preceding   sentence, for purposes of this paragraph, beneficial ownership shall be   calculated in accordance with Section 13(d) of the Securities Exchange Act of   1934, as amended.  For purposes of   this Warrant, in determining the number of outstanding shares of Common   Stock, the Holder may rely on the number of outstanding shares of Common   Stock as reflected in (1) the Company’s most recent Form 10-K, Form 10-Q,   Current Report on Form 8-K or other public filing with the Securities and   Exchange Commission, as the case may be, (2) a more recent public   announcement by the Company or (3) any other notice by the Company or the   Transfer Agent setting forth the number of shares of Common Stock   outstanding.  For any reason at any   time, upon the
written or oral request of the Holder, the Company shall   within one Business Day confirm orally and in writing to the Holder the   number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock   shall be determined after giving effect to the conversion or exercise of   securities of the Company, including the SPA Securities and the SPA Warrants,   by the Holder and its affiliates since the date as of which such number of   outstanding shares of Common Stock was reported.  By written notice to the Company, the Holder may increase or   decrease the Maximum Percentage to any other percentage not in excess of   9.99% specified in such notice; provided that (i) any such increase will not   be effective until the sixty-first (61st) day after such notice is   delivered to the Company, and (ii) any such increase or decrease will apply   only to the Holder and not to any other holder of SPA Securities.
  
	
   
  	
  
 
  
	
  
 
  	
  
          (ii)          Principal   Market Regulation.  The Company   shall not be obligated to issue any shares of Common Stock upon exercise of   this Warrant if the issuance of such shares of Common Stock would exceed that   number of shares of Common Stock which the Company may issue upon exercise or   conversion, as applicable, of the SPA Warrants and SPA Securities without   breaching the Company’s obligations under the rules or regulations of the   Nasdaq National Market or The Nasdaq Capital Market, as applicable (the “Exchange Cap”), except that such   limitation shall not apply in the event that the Company (A) obtains the   approval of its shareholders as required by the applicable rules of the   Nasdaq National Market or The Nasdaq Capital Market, as applicable, for   issuances of shares of Common Stock in excess of such
amount or (B) obtains a   written opinion from outside counsel to the Company that such approval is not   required, which opinion shall be reasonably satisfactory to the Required   Holders.  Until such
  

- 5 -

	
  
 
  	
  
approval or   written opinion is obtained, no Buyer shall be issued in the aggregate, upon   exercise or conversion, as applicable, of any SPA Warrants or SPA Securities,   shares of Common Stock in an amount greater than the product of the Exchange   Cap multiplied by a fraction, the numerator of which is the total number of   shares of Common Stock underlying the SPA Warrants issued to such Buyer   pursuant to the Exchange Agreements and the Securities Purchase Agreement on   the Issuance Date and the denominator of which is the aggregate number of   shares of Common Stock underlying the SPA Warrants issued to the Buyers   pursuant to the Exchange Agreements and the Securities Purchase Agreement on   the Issuance Date (with respect to each Buyer, the “Exchange Cap Allocation”).  In the event that any Buyer shall sell or   otherwise transfer any of such Buyer’s SPA Warrants, the transferee shall be   allocated a pro rata portion of such
Buyer’s Exchange Cap Allocation, and the   restrictions of the prior sentence shall apply to such transferee with   respect to the portion of the Exchange Cap Allocation allocated to such   transferee.  In the event that any   holder of SPA Warrants shall exercise all of such holder’s SPA Warrants into   a number of shares of Common Stock which, in the aggregate, is less than such   holder’s Exchange Cap Allocation, then the difference between such holder’s   Exchange Cap Allocation and the number of shares of Common Stock actually   issued to such holder shall be allocated to the respective Exchange Cap   Allocations of the remaining holders of SPA Warrants on a pro rata basis in   proportion to the shares of Common Stock underlying the SPA Warrants then   held by each such holder.  In the   event that the Company is prohibited from issuing any Warrant Shares for   which an Exercise Notice has been received as a result of the operation of   this Section 1(f)(ii), the
Company shall pay cash in exchange for   cancellation of such Warrant Shares, at a price per Warrant Share equal to   the difference between the Closing Sale Price and the Exercise Price as of   the date of the attempted exercise.
  

                    2.          ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES.  The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

                                        (a)          Adjustment upon Issuance of shares of Common Stock.  If and whenever on or after the Subscription Date the Company issues or sells, or in accordance with this Section 2 is deemed to have issued or sold, any shares of Common Stock (including the issuance or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding shares of Common Stock deemed to have been issued by the Company in connection with any Excluded Securities (as defined in the SPA Securities) for a consideration per share (the “New Issuance Price”) less than a price (the “Applicable Price”) equal to the Exercise Price in
effect immediately prior to such issue or sale or deemed issuance or sale (the 

- 6 -

foregoing a “Dilutive Issuance”), then immediately after such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the product of (A) the Exercise Price in effect immediately prior to such Dilutive Issuance and (B) the quotient determined by dividing (1) the sum of (I) the product derived by multiplying the Exercise Price in effect immediately prior to such Dilutive Issuance and the number of Common Stock Deemed Outstanding immediately prior to such Dilutive Issuance plus (II) the consideration, if any, received by the Company upon such Dilutive Issuance, by (2) the product derived by multiplying (I) the Exercise Price in effect immediately prior to such Dilutive Issuance by (II) the number of Common Stock Deemed Outstanding immediately after such Dilutive Issuance.  Upon each such adjustment of the Exercise Price hereunder, the number of Warrant Shares shall be
adjusted to the number of shares of Common Stock determined by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of Warrant Shares acquirable upon exercise of this Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment.  Notwithstanding the foregoing, if the Company issues or sells any shares of Common Stock, Options or Convertible Securities as payment of, or in exchange for, the XEL Notes, then immediately after such Dilutive Issuance the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price.  For purposes of determining the adjusted Exercise Price under this Section 2(a), the following shall be applicable:

	
  
 
  	
  
(i)          Issuance   of Options.  If the Company in any   manner grants any Options and the lowest price per share for which one share   of Common Stock is issuable upon the exercise of any such Option or upon   conversion, exercise or exchange of any Convertible Securities issuable upon   exercise of any such Option is less than the Applicable Price, then such   share of Common Stock shall be deemed to be outstanding and to have been   issued and sold by the Company at the time of the granting or sale of such   Option for such price per share.  For   purposes of this Section 2(a)(i), the “lowest price per share for which one   share of Common Stock is issuable upon exercise of such Options or upon   conversion, exercise or exchange of such Convertible Securities” shall be   equal to the sum of the lowest amounts of consideration (if any) received or   receivable by the Company with
respect to any one share of Common Stock upon   the granting or sale of the Option, upon exercise of the Option and upon   conversion, exercise or exchange of any Convertible Security issuable upon   exercise of such Option.  No further   adjustment of the Exercise Price or number of Warrant Shares shall be made   upon the actual issuance of such Common Stock or of such Convertible   Securities upon the exercise of such Options or upon the actual issuance of   such Common Stock upon conversion, exercise or exchange of such Convertible   Securities.
  
	
  
 
  	
  
 
  
	
  
 
  	
  
(ii)          Issuance   of Convertible Securities.  If the   Company in any manner issues or sells any Convertible Securities and the   lowest price per share for which one share of Common Stock is issuable upon   the conversion, exercise or exchange thereof is less than the Applicable   Price, then such share of Common Stock shall be deemed to be outstanding and   to have been issued and sold by the Company at the time of the issuance or   sale of
  

- 7 -

	
  
 
  	
  
such   Convertible Securities for such price per share.  For the purposes of this Section 2(a)(ii), the “lowest price   per share for which one share of Common Stock is issuable upon the   conversion, exercise or exchange” shall be equal to the sum of the lowest   amounts of consideration (if any) received or receivable by the Company with   respect to one share of Common Stock upon the issuance or sale of the   Convertible Security and upon conversion, exercise or exchange of such   Convertible Security.  No further   adjustment of the Exercise Price or number of Warrant Shares shall be made   upon the actual issuance of such Common Stock upon conversion, exercise or   exchange of such Convertible Securities, and if any such issue or sale of   such Convertible Securities is made upon exercise of any Options for which   adjustment of this Warrant has been or is to be made pursuant to other   provisions of this Section 2(a), no further
adjustment of the Exercise Price   or number of Warrant Shares shall be made by reason of such issue or sale.
  
	
  
 
  	
  
 
  
	
  
 
  	
  
(iii)          Change   in Option Price or Rate of Conversion.    If the purchase price provided for in any Options, the additional   consideration, if any, payable upon the issue, conversion, exercise or   exchange of any Convertible Securities, or the rate at which any Convertible   Securities are convertible into or exercisable or exchangeable for shares of   Common Stock increases or decreases at any time, the Exercise Price and the   number of Warrant Shares in effect at the time of such increase or decrease   shall be adjusted to the Exercise Price and the number of Warrant Shares   which would have been in effect at such time had such Options or Convertible   Securities provided for such increased or decreased purchase price,   additional consideration or increased or decreased conversion rate, as the   case may be, at the time initially granted, issued or sold.  For purposes of this Section
2(a)(iii), if   the terms of any Option or Convertible Security that was outstanding as of   the date of issuance of this Warrant are increased or decreased in the manner   described in the immediately preceding sentence, then such Option or   Convertible Security and the shares of Common Stock deemed issuable upon   exercise, conversion or exchange thereof shall be deemed to have been issued   as of the date of such increase or decrease.    No adjustment pursuant to this Section 2(a) shall be made if such   adjustment would result in an increase of the Exercise Price then in effect   or a decrease in the number of Warrant Shares.
  
	
   
  	
  
 
  
	
  
 
  	
  
(iv)          Calculation   of Consideration Received.  In   case any Option is issued in connection with the issue or sale of other   securities of the Company, together comprising one integrated transaction in   which no specific consideration is allocated to such Options by the parties   thereto, the Options will be deemed to have been issued for a consideration   of $.01.  If any shares of Common   Stock, Options or Convertible Securities are issued or sold or deemed to have   been issued or sold for cash, the consideration received therefor will be   deemed to be the net amount
  

- 8 -

	
  
 
  	
  
received by   the Company therefor.  If any shares   of Common Stock, Options or Convertible Securities are issued or sold for a   consideration other than cash, the amount of such consideration other than   cash received by the Company will be the fair value of such consideration,   except where such consideration consists of marketable securities, in which   case the amount of consideration received by the Company will be the Closing   Sale Price of such security on the date of receipt.  If any shares of Common Stock, Options or Convertible   Securities are issued to the shareholders of the non-surviving entity in   connection with any merger in which the Company is the surviving entity, the   amount of such consideration will be deemed to be the fair value of the net   assets and business of the non-surviving entity, calculated on a   going-concern basis, as is attributable to such shares of Common Stock,   Options or Convertible Securities, as the
case may be.  The fair value of any consideration other   than cash or securities will be determined jointly by the Company and the   Required Holders.  If such parties are   unable to reach agreement within ten (10) days after the occurrence of an   event requiring valuation (the “Valuation   Event”), the fair value of such consideration will be determined   within five (5) Business Days after the tenth day following the Valuation   Event by an independent, reputable appraiser jointly selected by the Company   and the Required Holders.  The determination   of such appraiser shall be final and binding upon all parties absent manifest   error and the fees and expenses of such appraiser shall be borne one-half by   the Company and one-half by the Holders.    The consideration received by the Company need not be calculated for   shares of Common Stock that are issued or sold or deemed issued or sold to   the extent they constitute Excluded Securities.

	
   
  	
  
 
  
	
  
 
  	
  
(v)          Record   Date.  If the Company takes a   record of the holders of shares of Common Stock for the purpose of entitling   them (A) to receive a dividend or other distribution payable in shares   of Common Stock, Options or in Convertible Securities or (B) to   subscribe for or purchase shares of Common Stock, Options or Convertible   Securities, then such record date will be deemed to be the date of the issue   or sale of the shares of Common Stock deemed to have been issued or sold upon   the declaration of such dividend or the making of such other distribution or   the date of the granting of such right of subscription or purchase, as the   case may be.
  
	
  
 
  	
  
 
  
	
  
 
  	
  
(vi)          Until   such time as the Company receives the Stockholder Approval (as defined in the   Securities Purchase Agreement), no adjustment pursuant to Section 2(a) shall   cause the Exercise Price to be less than $0.70, as adjusted for any stock   dividend, stock split, stock combination, reclassification or similar   transaction.
  

                                         (b)          Adjustment upon Subdivision or Combination of shares of Common Stock.  If the Company at any time on or after the Subscription Date subdivides (by any stock

- 9 -

split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased.  If the Company at any time on or after the Subscription Date  combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased.  Any adjustment under this Section 2(b) shall become effective at the close of business on the date the subdivision or combination becomes effective.

 

                                        (c)          Other Events.  If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Company’s Board of Directors will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment pursuant to this Section 2(c) will increase the Exercise Price or decrease the number
of Warrant Shares as otherwise determined pursuant to this Section 2.

 

                    3.          RIGHTS UPON DISTRIBUTION OF ASSETS.  If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) for which adjustment in the Exercise Price of the Warrant is not otherwise provided hereunder (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case:

                                       (a)          any Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date, to a price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall be the Closing Bid Price of the shares of Common Stock on the trading day immediately preceding such record date minus the value of the Distribution (as determined in good faith by the Company’s Board of Directors) applicable to one share of shares of Common Stock, and (ii) the denominator
shall be the Closing Bid Price of the shares of Common Stock on the trading day immediately preceding such record date; and

- 10 -

                                       (b)          the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding paragraph (a).

                    4.          FUNDAMENTAL TRANSACTIONS.  

                                        (a)          The Company shall not enter into or be party to a Fundamental Transaction unless (i)  the Successor Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section (4)(a) pursuant to written agreements in form and substance satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transaction, including agreements to deliver to each holder of Warrants in exchange for such Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant,
including, without limitation, an adjusted exercise price equal to the value for the shares of Common Stock reflected by the terms of such Fundamental Transaction, and exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and satisfactory to the Required Holders and (ii) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market.  Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and
shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.  Upon consummation of the Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been exercised immediately prior to such Fundamental Transaction, as adjusted in accordance with the provisions of this Warrant.  In addition to and not in substitution
for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the Fundamental Transaction but prior to the Expiration Date, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had the

- 11 -

Warrant been exercised immediately prior to such Fundamental Transaction.  Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Required Holders.  The provisions of this Section shall apply similarly and equally to successive Fundamental Transactions and Corporate Events.  Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Required Holders.  The provisions of this Section shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to any limitations on the exercise of this Warrant.  

                                        (b)          In the event of a Fundamental Transaction, if the Successor Entity is unable to deliver to the Holder the warrant referred to in Section 4(a) and the Holder has not exercised the Warrant in full prior to the consummation of the Fundamental Transaction, then the Company may enter into a Fundamental Transaction pursuant to which the Holder shall receive, simultaneously with the consummation of the Fundamental Transaction, in lieu of the warrant referred to in Section 4(a) cash in an amount equal to the value of the remaining unexercised portion of this Warrant on the date of such consummation, which value shall be determined by use of the Black and Scholes Option
Pricing Model.  Provision made pursuant to this Section shall be in a form and substance reasonably satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transactions.  The provisions of this Section shall apply similarly and equally to successive Fundamental Transactions.

                    5.          NONCIRCUMVENTION.  The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation, Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.  Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect,
(ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the SPA Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the SPA Warrants, 130% of the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the SPA Warrants then outstanding (without regard to any limitations on exercise).

                    6.          WARRANT HOLDER NOT DEEMED A STOCKHOLDER.  Except as otherwise specifically provided herein, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior
to the issuance to the Holder of the Warrant

- 12 -

Shares which such Person is then entitled to receive upon the due exercise of this Warrant.  In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.  Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company generally, contemporaneously with the giving thereof to the shareholders.

                    7.          REISSUANCE OF WARRANTS.

                                        (a)          Transfer of Warrant.  If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less then the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

                                        (b)          Lost, Stolen or Mutilated Warrant.  Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.

                                        (c)          Exchangeable for Multiple Warrants.  This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrants for fractional shares of Common Stock shall be given.

                                        (d)          Issuance of New Warrants.  Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant),
(iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

- 13 -

                    8.          NOTICES.  Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the Securities Purchase Agreement.  The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefore.  Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen days (or such lesser period agreed to in writing by the Required Holders) prior to the date on which
the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to all holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

                    9.          AMENDMENT AND WAIVER.  Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Required Holders; provided that no such action may increase the exercise price of any SPA Warrant or decrease the number of shares or class of stock obtainable upon exercise of any SPA Warrant without the written consent of the Holder.  No such amendment shall be effective to the extent that it applies to less than all of the holders of the SPA Warrants then outstanding.

                    10.          GOVERNING LAW.  This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

                    11.          CONSTRUCTION; HEADINGS.  This Warrant shall be deemed to be jointly drafted by the Company and all the Buyers and shall not be construed against any person as the drafter hereof.  The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.

                    12.          DISPUTE RESOLUTION.  In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two Business Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder.  If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank
selected by the Company and approved by the Holder  or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent,

- 14 -

outside accountant.  The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten Business Days from the time it receives the disputed determinations or calculations.  Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.  

                    13.          REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF.  The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder right to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.  The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this
Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

                    14.          TRANSFER.          (a)This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company, except as may otherwise be required by Section 2(f) of the Securities Purchase Agreement.  Each Person to whom this Warrant is sold, assigned or transferred by the Holder shall provide to the Company true and accurate information as to such Person comparable to that contained in columns (1), (2) and (7) of the Schedule of Buyers attached to the Securities Purchase Agreement and as to the jurisdiction of residence of such Person.

                                        (b)          The Company shall be entitled to treat the registered Holder of this Warrant as the absolute owner hereof and shall incur no liability for the issuance of Common Stock or for other action taken hereunder in good faith based upon such ownership until such time as a written assignment of this Warrant is effected by such registered owner, which assignment has been delivered to the Company and satisfies the requirements of Sections 7(a) and 14(a) hereof.

                    15.          CERTAIN DEFINITIONS.  For purposes of this Warrant, the following terms shall have the following meanings:

                                        (a)          “Bloomberg” means Bloomberg Financial Markets.

                                        (b)          “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.

                                        (c)          “Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing

- 15 -

trade price, as the case may be, then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York Time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC
(formerly the National Quotation Bureau, Inc.).  If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.  If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12.  All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

                                        (d)          “Common Stock” means (i) the Company’s shares of Common Stock, par value $0.01 per share, and (ii) any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock.

                                        (e)          “Common Stock Deemed Outstanding” means, at any given time, the number of shares of Common Stock actually outstanding at such time, plus the number of shares of Common Stock deemed to be outstanding pursuant to Sections 2(a)(i) and 2(a)(ii) hereof regardless of whether the Options or Convertible Securities are actually exercisable at such time, but excluding any shares of Common Stock owned or held by or for the account of the Company or issuable upon conversion and exercise, as applicable, of the SPA Securities and the Warrants.

                                        (f)          “Convertible Securities” means any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.

                                        (g)          “Eligible Market” means the Principal Market, The New York Stock Exchange, Inc., the American Stock Exchange or The Nasdaq Capital Market.

                                        (h)          “Expiration Date” means the date sixty months after March 21, 2005  or, if such date falls on a day other than a Business Day or on which trading does not take place on the Principal Market (a “Holiday”), the next date that is not a Holiday.

                                        (i)          “Fundamental Transaction” means that the Company shall, directly or indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, (iii) allow another Person to make a purchase, tender or exchange offer that is

- 16 -

accepted by the holders of more than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer) or (iv) consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination), or (iv) reorganize, recapitalize or reclassify its Common Stock.

                                        (j)          “Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

                                        (k)          “Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

                                        (l)          “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

                                        (m)          “Principal Market” means the Nasdaq National Market.

                                        (n)          “Registration Rights Agreement” means that certain registration rights agreement by and among the Company and the Buyers.

                                        (o)          “Required Holders” means the holders of the SPA Warrants representing at least a majority of shares of Common Stock underlying the SPA Warrants then outstanding.

                                        (p)          “SPA Securities” means the Notes issued pursuant to the Securities Purchase Agreement.

                                        (q)          “Successor Entity” means the Person (or, if so elected by the Required Holders, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered into.

                                        (r)          “XEL Notes” means the convertible promissory notes in the original aggregate principal amount of $10,480,000 due February 5, 2006 issued in connection with the acquisition by the Company of XEL Communications, Inc. and having an outstanding principal balance in the aggregate not in excess of $2,900,000 as of the Subscription Date as amended by the XEL Amendment (as defined in the Exchange Agreement); provided, however, that such notes shall not be amended, restated, renewed, refunded, refinanced or otherwise extended and

- 17 -

the outstanding principal balance shall not be increased after the Subscription Date without the consent of the Required Holders.

[Signature Page Follows]

- 18 -

          IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.

	
  
 
  	
  
VERILINK CORPORATION
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
By:
  	
  
 
  
	
  
 
  	
  
 
  	
  

  
	
  
 
  	
  
Name:
  	
  
 
  
	
  
 
  	
  
Title:
  	
  
 
  

- 19 -

EXHIBIT A

SERIES A EXERCISE NOTICE

TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS
 WARRANT TO PURCHASE COMMON STOCK

VERILINK CORPORATION

          The undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Warrant Shares”) of Verilink Corporation, a Delaware corporation (the “Company”), evidenced by the attached Warrant to Purchase Common Stock (the “Warrant”).  Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

          1.  Form of Exercise Price.  The Holder intends that payment of the Exercise Price shall be made as:

                    ____________ a “Cash Exercise” with respect to _________________ Warrant Shares; and/or

                    ____________ a “Cashless Exercise” with respect to _______________ Warrant Shares.

          2.  Payment of Exercise Price.  In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in accordance with the terms of the Warrant.

          3.  Delivery of Warrant Shares.  The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of the Warrant.

          4.  The undersigned confirms that the Warrant Shares have been sold in compliance with the applicable Registration Statement (as defined in the Registration Rights Agreement) relative to the registration for resale of such Warrant Shares.

                              Yes ______          No_______

Notwithstanding anything to the contrary contained herein, this Exercise Notice shall constitute a representation by the undersigned that, after giving effect to the transactions contemplated hereby, the undersigned (together with its affiliates) will not have beneficial ownership (together with the beneficial ownership of such Person’s affiliates) of a number of shares of Common Stock which exceeds the Maximum Percentage.

	
  
Date:                         ,               
  	
  
 
  
	
  
 
  	
  
 
  
	
  
 
  	
  
 
  
	
  

  	
  
 
  
	
  Name of Registered Holder
  	
  
 
  

	
  
By:
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  

  	
  
 
  
	
  
 
  	
  
Name:
  	
  
 
  
	
  
 
  	
  
Title:
  	
  
 
  

ACKNOWLEDGMENT

          The Company hereby acknowledges this Exercise Notice and hereby directs American Stock Transfer & Trust Company to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated March 21, 2005 and March 9, 2006 from the Company and acknowledged and agreed to by American Stock Transfer & Trust Company.

	
  
 
  	
  
VERILINK CORPORATION
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
By:
  	
  
 
  
	
  
 
  	
  
 
  	
  

  
	
  
 
  	
  
 
  	
  
Name:
  
	
   
  	
   
  	
  Title:Exhibit 10.18

FORM OF SERIES B WARRANT

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, (B) AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (C) REASONABLE ASSURANCE HAVING BEEN PROVIDED TO THE COMPANY THAT SUCH OFFER, SALE, ASSIGNMENT OR TRANSFER IS BEING MADE PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.  NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

VERILINK CORPORATION

SERIES B WARRANT TO PURCHASE COMMON STOCK

Warrant No.: B-__
 Number of Shares of Common Stock: ______
 Date of Issuance: March 9, 2006 (“Issuance Date”)

                    Verilink Corporation, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, __________________, the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), at any time or times on or after the Issuance Date but not after 11:59 p.m., New York Time, on the Expiration Date (as defined below), _______ fully paid nonassessable shares of Common Stock (as defined below)(the
“Warrant Shares”).  Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 15.  

                    This Warrant is one of an issue of warrants to purchase Common Stock (the “Additional SPA Warrants”, and together with the Replacement Warrants (as defined in the Exchange Agreements (as defined below)), the “SPA Warrants”) issued pursuant to the Consent, Amendment and Exchange Agreement, dated as of March 9, 2006, by and between the Company and the Holder (the “Exchange Agreement”, and together with the other Consent, Amendment and Exchange Agreements, each dated as of March 9, 2006, by and among the Company and each of the other Buyers, the “Exchange Agreements”).

                    1.     EXERCISE OF WARRANT.

                                        (a)     Mechanics of Exercise.  Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by the Holder on any day on or after September 21, 2005 in whole or in part, by (i) delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant, (ii) (A) payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”) in cash or wire transfer of
immediately available funds or (B) by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)).  The Holder shall not be required to deliver the original Warrant in order to effect the exercise hereunder.  Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.  On or before the first Business Day following the date on which the Company has received each of the Exercise Notice and the Aggregate Exercise Price (or notice of a Cashless Exercise) (the “Exercise Delivery Documents”), the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of the Exercise Delivery Documents to the Holder and the Company’s transfer agent (the “Transfer Agent”).  On or
before the third Business Day following the date on which the Company has received all of the Exercise Delivery Documents (the “Share Delivery Date”), the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program and such action is not prohibited by applicable law or regulation or any applicable policy of DTC, upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission system, or (Y) if the foregoing shall not apply, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is
entitled pursuant to such exercise.  Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares.  If this Warrant is delivered to the Company in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than five Business Days after the Share Delivery Date and at its own expense, issue a new Warrant (in accordance with Section 7(d)) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this
Warrant is exercised.  No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number.  The Company shall pay any and all taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant; provided that the Company shall not be required to pay any tax that may be payable in respect of any issuance and delivery of Warrant Shares to any Person other than the Holder or with respect to any income tax due by the Holder with respect to such Warrant Shares.  

- 2 -

                                        (b)     Exercise Price.  For purposes of this Warrant, “Exercise Price” means $1.00, subject to adjustment as provided herein.

                                        (c)     Company’s Failure to Timely Deliver Securities.  If the Company shall fail for any reason or for no reason to issue to the Holder on or before the Share Delivery Date, a certificate for the number of shares of Common Stock to which the Holder is entitled and register such shares of Common Stock on the Company’s share register or to credit the Holder’s balance account with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder’s exercise of this Warrant, then, in addition to all other remedies available to the Holder, the Company shall pay in cash to the Holder on each day after such Share Delivery Date that the issuance of
such shares of Common Stock is not timely effected an amount equal to 2.0% of the product of (A) the sum of the number of shares of Common Stock not issued to the Holder on a timely basis and to which the Holder is entitled and (B) the Closing Sale Price of the shares of Common Stock on the trading day immediately preceding the last possible date which the Company could have issued such shares of Common Stock to the Holder without violating Section 1(a).  In addition to the foregoing, if on or before the Share Delivery Date the Company shall fail to issue and deliver a certificate to the Holder and register such shares of Common Stock on the Company’s share register or credit the Holder’s balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon such holder’s exercise hereunder, and if on or after such Share Delivery Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction
of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a “Buy-In”), then the Company shall, within three Business Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such certificate (and to issue such shares of Common Stock) shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such shares of Common Stock and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the Closing Bid Price on the date of exercise.

                                        (d)     Cashless Exercise.  Notwithstanding anything contained herein to the contrary, if a Registration Statement (as defined in the Registration Rights Agreement) covering the Warrant Shares that are the subject of the Exercise Notice (the “Unavailable Warrant Shares”) is not available for the resale of such Unavailable Warrant Shares, the Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common Stock
determined according to the following formula (a “Cashless Exercise”):

- 3 -

                                        Net Number = (A x B) - (A x C)
                                                                            B

                                        For purposes of the foregoing formula:

	
  
 
  	
  
A= the total   number of shares with respect to which this Warrant is then being exercised.
  
	
  
 
  	
  
 
  
	
  
 
  	
  
B= the   Closing Sale Price of the shares of Common Stock (as reported by Bloomberg)   on the date immediately preceding the date of the Exercise Notice.
  
	
  
 
  	
  
 
  
	
  
 
  	
  
C= the   Exercise Price then in effect for the applicable Warrant Shares at the time   of such exercise.
  

                                        (e)     Disputes.  In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12.

                                        (f)     Limitations on Exercises.

	
  
 
  	
  
(i)          Beneficial   Ownership.  Other than in   connection with a Fundamental Transaction pursuant to Section 4(a), the   Company shall not effect the exercise of this Warrant, and the Holder shall   not have the right to exercise this Warrant, to the extent that after giving   effect to such exercise, such Person (together with such Person’s affiliates)   would beneficially own in excess of 4.99% (the “Maximum Percentage”) of the shares of Common Stock   outstanding immediately after giving effect to such exercise.  For purposes of the foregoing sentence,   the aggregate number of shares of Common Stock beneficially owned by such   Person and its affiliates shall include the number of shares of Common Stock   issuable upon exercise of this Warrant with respect to which the   determination of such sentence is being made, but shall exclude shares of Common   Stock which
would be issuable upon (i) exercise of the remaining, unexercised   portion of this Warrant beneficially owned by such Person and its affiliates   and (ii) exercise or conversion of the unexercised or unconverted portion of   any other securities of the Company beneficially owned by such Person and its   affiliates (including, without limitation, any convertible notes or   convertible preferred stock or warrants) subject to a limitation on   conversion or exercise analogous to the limitation contained herein.  Except as set forth in the preceding   sentence, for purposes of this paragraph, beneficial ownership shall be   calculated in accordance with Section 13(d) of the Securities Exchange Act of   1934, as amended.  For purposes of   this Warrant, in determining the number of outstanding shares of Common   Stock, 
  

- 4 -

	
  
 
  	
  
the Holder   may rely on the number of outstanding shares of Common Stock as reflected in   (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form   8-K or other public filing with the Securities and Exchange Commission, as   the case may be, (2) a more recent public announcement by the Company or (3)   any other notice by the Company or the Transfer Agent setting forth the   number of shares of Common Stock outstanding.  For any reason at any time, upon the written or oral request of   the Holder, the Company shall within one Business Day confirm orally and in   writing to the Holder the number of shares of Common Stock then   outstanding.  In any case, the number   of outstanding shares of Common Stock shall be determined after giving effect   to the conversion or exercise of securities of the Company, including the SPA   Securities and the SPA Warrants, by the Holder and its affiliates since the   date as of which such number
of outstanding shares of Common Stock was   reported.  By written notice to the   Company, the Holder may increase or decrease the Maximum Percentage to any   other percentage not in excess of 9.99% specified in such notice; provided   that (i) any such increase will not be effective until the sixty-first (61st)   day after such notice is delivered to the Company, and (ii) any such increase   or decrease will apply only to the Holder and not to any other holder of SPA   Securities.
  
	
  
 
  	
  
 
  
	
  
 
  	
  
(ii)         Principal   Market Regulation.  The Company   shall not be obligated to issue any shares of Common Stock upon exercise of   this Warrant if the issuance of such shares of Common Stock would exceed that   number of shares of Common Stock which the Company may issue upon exercise or   conversion, as applicable, of the SPA Warrants and SPA Securities without   breaching the Company’s obligations under the rules or regulations of the   Nasdaq National Market or The Nasdaq Capital Market, as applicable (the “Exchange Cap”), except that such   limitation shall not apply in the event that the Company (A) obtains the   approval of its shareholders as required by the applicable rules of the   Nasdaq National Market or The Nasdaq Capital Market, as applicable, for   issuances of shares of Common Stock in excess of such amount or (B) obtains a   written opinion from outside counsel to
the Company that such approval is not   required, which opinion shall be reasonably satisfactory to the Required   Holders.  Until such approval or   written opinion is obtained, no Buyer shall be issued in the aggregate, upon   exercise or conversion, as applicable, of any SPA Warrants or SPA Securities,   shares of Common Stock in an amount greater than the product of the Exchange   Cap multiplied by a fraction, the numerator of which is the total number of   shares of Common Stock underlying the SPA Warrants issued to such Buyer   pursuant to the Exchange Agreements and the Securities Purchase
  

- 5 -

	
  
 
  	
  
Agreement   on the Issuance Date and the denominator of which is the aggregate number of   shares of Common Stock underlying the SPA Warrants issued to the Buyers   pursuant to the Exchange Agreements and the Securities Purchase Agreement on   the Issuance Date (with respect to each Buyer, the “Exchange Cap Allocation”).  In the event that any Buyer shall sell or   otherwise transfer any of such Buyer’s SPA Warrants, the transferee shall be   allocated a pro rata portion of such Buyer’s Exchange Cap Allocation, and the   restrictions of the prior sentence shall apply to such transferee with   respect to the portion of the Exchange Cap Allocation allocated to such   transferee.  In the event that any   holder of SPA Warrants shall exercise all of such holder’s SPA Warrants into   a number of shares of Common Stock which, in the aggregate, is less than such   holder’s Exchange Cap Allocation, then the difference
between such holder’s   Exchange Cap Allocation and the number of shares of Common Stock actually   issued to such holder shall be allocated to the respective Exchange Cap   Allocations of the remaining holders of SPA Warrants on a pro rata basis in   proportion to the shares of Common Stock underlying the SPA Warrants then   held by each such holder.  In the   event that the Company is prohibited from issuing any Warrant Shares for   which an Exercise Notice has been received as a result of the operation of   this Section 1(f)(ii), the Company shall pay cash in exchange for   cancellation of such Warrant Shares, at a price per Warrant Share equal to   the difference between the Closing Sale Price and the Exercise Price as of   the date of the attempted exercise.
  

                    2.     ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES.  The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

                                        (a)     Adjustment upon Issuance of shares of Common Stock.  If and whenever on or after the Subscription Date the Company issues or sells, or in accordance with this Section 2 is deemed to have issued or sold, any shares of Common Stock (including the issuance or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding shares of Common Stock deemed to have been issued by the Company in connection with any Excluded Securities (as defined in the SPA Securities) for a consideration per share (the “New Issuance Price”) less than a price (the “Applicable Price”) equal to the Exercise Price in effect immediately prior to
such issue or sale or deemed issuance or sale (the foregoing a “Dilutive Issuance”), then immediately after such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the product of (A) the Exercise Price in effect immediately prior to such Dilutive Issuance and (B) the quotient determined by dividing (1) the sum of (I) the product derived by multiplying the Exercise 

- 6 -

Price in effect immediately prior to such Dilutive Issuance and the number of Common Stock Deemed Outstanding immediately prior to such Dilutive Issuance plus (II) the consideration, if any, received by the Company upon such Dilutive Issuance, by (2) the product derived by multiplying (I) the Exercise Price in effect immediately prior to such Dilutive Issuance by (II) the number of Common Stock Deemed Outstanding immediately after such Dilutive Issuance.  Upon each such adjustment of the Exercise Price hereunder, the number of Warrant Shares shall be adjusted to the number of shares of Common Stock determined by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of Warrant Shares acquirable upon exercise of this Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment.  Notwithstanding the foregoing, if the Company issues or
sells any shares of Common Stock, Options or Convertible Securities as payment of, or in exchange for, the XEL Notes, then immediately after such Dilutive Issuance the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price.  For purposes of determining the adjusted Exercise Price under this Section 2(a), the following shall be applicable:

	
  
 
  	
  
 
  	
  
(i)          Issuance   of Options.  If the Company in any   manner grants any Options and the lowest price per share for which one share   of Common Stock is issuable upon the exercise of any such Option or upon   conversion, exercise or exchange of any Convertible Securities issuable upon   exercise of any such Option is less than the Applicable Price, then such   share of Common Stock shall be deemed to be outstanding and to have been   issued and sold by the Company at the time of the granting or sale of such   Option for such price per share.  For   purposes of this Section 2(a)(i), the “lowest price per share for which one   share of Common Stock is issuable upon exercise of such Options or upon   conversion, exercise or exchange of such Convertible Securities” shall be   equal to the sum of the lowest amounts of consideration (if any) received or   receivable by the Company with
respect to any one share of Common Stock upon   the granting or sale of the Option, upon exercise of the Option and upon   conversion, exercise or exchange of any Convertible Security issuable upon   exercise of such Option.  No further   adjustment of the Exercise Price or number of Warrant Shares shall be made   upon the actual issuance of such Common Stock or of such Convertible   Securities upon the exercise of such Options or upon the actual issuance of   such Common Stock upon conversion, exercise or exchange of such Convertible   Securities.
  
	
  
 
  	
  
 
  	
  
 
  
	
   
  	
  
 
  	
  
(ii)          Issuance   of Convertible Securities.  If the   Company in any manner issues or sells any Convertible Securities and the   lowest price per share for which one share of Common Stock is issuable upon   the conversion, exercise or exchange thereof is less than the Applicable   Price, then such share of Common Stock shall be deemed to be outstanding and   to have been issued and sold by the Company at the time of the issuance or   sale of such Convertible Securities for such price per share.  For the purposes of this Section 2(a)(ii),   the “lowest price per share for which one share of Common Stock is issuable   upon the conversion, exercise or exchange” shall be equal to the sum of the   lowest amounts of consideration (if any) received or receivable by the Company   with respect to one share of Common Stock upon the issuance or sale of the   Convertible Security and

  

- 7 -

	
  
 
  	
  
 
  	
  
upon   conversion, exercise or exchange of such Convertible Security.  No further adjustment of the Exercise   Price or number of Warrant Shares shall be made upon the actual issuance of   such Common Stock upon conversion, exercise or exchange of such Convertible   Securities, and if any such issue or sale of such Convertible Securities is   made upon exercise of any Options for which adjustment of this Warrant has   been or is to be made pursuant to other provisions of this Section 2(a), no   further adjustment of the Exercise Price or number of Warrant Shares shall be   made by reason of such issue or sale.
  
	
   
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
(iii)          Change   in Option Price or Rate of Conversion.    If the purchase price provided for in any Options, the additional   consideration, if any, payable upon the issue, conversion, exercise or   exchange of any Convertible Securities, or the rate at which any Convertible   Securities are convertible into or exercisable or exchangeable for shares of   Common Stock increases or decreases at any time, the Exercise Price and the   number of Warrant Shares in effect at the time of such increase or decrease   shall be adjusted to the Exercise Price and the number of Warrant Shares   which would have been in effect at such time had such Options or Convertible   Securities provided for such increased or decreased purchase price,   additional consideration or increased or decreased conversion rate, as the   case may be, at the time initially granted, issued or sold.  For purposes of this Section
2(a)(iii), if   the terms of any Option or Convertible Security that was outstanding as of   the date of issuance of this Warrant are increased or decreased in the manner   described in the immediately preceding sentence, then such Option or   Convertible Security and the shares of Common Stock deemed issuable upon   exercise, conversion or exchange thereof shall be deemed to have been issued   as of the date of such increase or decrease.    No adjustment pursuant to this Section 2(a) shall be made if such   adjustment would result in an increase of the Exercise Price then in effect   or a decrease in the number of Warrant Shares.
  
	
  
 
  	
  
 
  	
  
 
  
	
   
  	
  
 
  	
  
(iv)          Calculation   of Consideration Received.  In   case any Option is issued in connection with the issue or sale of other   securities of the Company, together comprising one integrated transaction in   which no specific consideration is allocated to such Options by the parties   thereto, the Options will be deemed to have been issued for a consideration   of $.01.  If any shares of Common   Stock, Options or Convertible Securities are issued or sold or deemed to have   been issued or sold for cash, the consideration received therefor will be   deemed to be the net amount received by the Company therefor.  If any shares of Common Stock, Options or   Convertible Securities are issued or sold for a consideration other than   cash, the amount of such consideration other than cash received by the   Company will be the fair value of such consideration, except where such   consideration
consists of marketable securities, in which case the amount of   consideration received by the Company will be the Closing 
  

- 8 -

	
  
 
  	
  
 
  	
  
Sale Price   of such security on the date of receipt.    If any shares of Common Stock, Options or Convertible Securities are   issued to the shareholders of the non-surviving entity in connection with any   merger in which the Company is the surviving entity, the amount of such   consideration will be deemed to be the fair value of the net assets and   business of the non-surviving entity, calculated on a going-concern basis, as   is attributable to such shares of Common Stock, Options or Convertible   Securities, as the case may be.  The   fair value of any consideration other than cash or securities will be   determined jointly by the Company and the Required Holders.  If such parties are unable to reach   agreement within ten (10) days after the occurrence of an event requiring valuation   (the “Valuation Event”), the   fair value of such consideration will be determined within five (5) Business   Days after the tenth day
following the Valuation Event by an independent,   reputable appraiser jointly selected by the Company and the Required Holders.  The determination of such appraiser shall   be final and binding upon all parties absent manifest error and the fees and   expenses of such appraiser shall be borne one-half by the Company and   one-half by the Holders.  The   consideration received by the Company need not be calculated for shares of   Common Stock that are issued or sold or deemed issued or sold to the extent   they constitute Excluded Securities.
  
	
   
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
(v)          Record   Date.  If the Company takes a   record of the holders of shares of Common Stock for the purpose of entitling   them (A) to receive a dividend or other distribution payable in shares   of Common Stock, Options or in Convertible Securities or (B) to   subscribe for or purchase shares of Common Stock, Options or Convertible   Securities, then such record date will be deemed to be the date of the issue   or sale of the shares of Common Stock deemed to have been issued or sold upon   the declaration of such dividend or the making of such other distribution or   the date of the granting of such right of subscription or purchase, as the   case may be.
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
(vi)          Until   such time as the Company receives the Stockholder Approval (as defined in the   Securities Purchase Agreement), no adjustment pursuant to Section 2(a) shall   cause the Exercise Price to be less than $0.70, as adjusted for any stock   dividend, stock split, stock combination, reclassification or similar   transaction.
  

                                        (b)     Adjustment upon Subdivision or Combination of shares of Common Stock.  If the Company at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased.  If the Company at any time on or after the Subscription Date  combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of
shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased.  Any adjustment under this Section 2(b) shall become effective at the close of business on the date the subdivision or combination becomes effective.

- 9 -

                                        (c)     Other Events.  If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Company’s Board of Directors will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment pursuant to this Section 2(c) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2.

                    3.     RIGHTS UPON DISTRIBUTION OF ASSETS.  If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) for which adjustment in the Exercise Price of the Warrant is not otherwise provided hereunder (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case:

                                        (a)     any Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date, to a price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall be the Closing Bid Price of the shares of Common Stock on the trading day immediately preceding such record date minus the value of the Distribution (as determined in good faith by the Company’s Board of Directors) applicable to one share of shares of Common Stock, and (ii) the denominator shall be the Closing Bid Price of
the shares of Common Stock on the trading day immediately preceding such record date; and

                                        (b)     the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding paragraph (a).

                    4.     FUNDAMENTAL TRANSACTIONS.  

                                        (a)     The Company shall not enter into or be party to a Fundamental Transaction unless (i)  the Successor Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section (4)(a) pursuant to written agreements in form and substance satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transaction, including agreements to deliver to each holder of Warrants in exchange for such Warrants a security of the Successor Entity evidenced by a written instrument 

- 10 -

substantially similar in form and substance to this Warrant, including, without limitation, an adjusted exercise price equal to the value for the shares of Common Stock reflected by the terms of such Fundamental Transaction, and exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and satisfactory to the Required Holders and (ii) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market.  Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.  Upon consummation of the Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been exercised immediately prior to such Fundamental Transaction, as
adjusted in accordance with the provisions of this Warrant.  In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the Fundamental Transaction but prior to the Expiration Date, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive
upon the happening of such Fundamental Transaction had the Warrant been exercised immediately prior to such Fundamental Transaction.  Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Required Holders.  The provisions of this Section shall apply similarly and equally to successive Fundamental Transactions and Corporate Events.  Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Required Holders.  The provisions of this Section shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to any limitations on the exercise of this Warrant.  

                                        (b)     In the event of a Fundamental Transaction, if the Successor Entity is unable to deliver to the Holder the warrant referred to in Section 4(a) and the Holder has not exercised the Warrant in full prior to the consummation of the Fundamental Transaction, then the Company may enter into a Fundamental Transaction pursuant to which the Holder shall receive, simultaneously with the consummation of the Fundamental Transaction, in lieu of the warrant referred to in Section 4(a) cash in an amount equal to the value of the remaining unexercised

- 11 -

portion of this Warrant on the date of such consummation, which value shall be determined by use of the Black and Scholes Option Pricing Model.  Provision made pursuant to this Section shall be in a form and substance reasonably satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transactions.  The provisions of this Section shall apply similarly and equally to successive Fundamental Transactions.

                    5.     NONCIRCUMVENTION.  The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation, Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.  Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such
actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the SPA Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the SPA Warrants, 130% of the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the SPA Warrants then outstanding (without regard to any limitations on exercise).

                    6.     WARRANT HOLDER NOT DEEMED A STOCKHOLDER.  Except as otherwise specifically provided herein, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder
of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant.  In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.  Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company generally, contemporaneously with the giving thereof to the shareholders.

                    7.     REISSUANCE OF WARRANTS.

                                        (a)     Transfer of Warrant.  If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less then the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

- 12 -

                                        (b)     Lost, Stolen or Mutilated Warrant.  Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.

                                        (c)     Exchangeable for Multiple Warrants.  This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrants for fractional shares of Common Stock shall be given.

                                        (d)     Issuance of New Warrants.  Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance
date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

- 13 -

                    8.     NOTICES.  Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the Securities Purchase Agreement.  The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefore.  Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen days (or such lesser period agreed to in writing by the Required Holders) prior to the date on which the Company closes its books
or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to all holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

                    9.     AMENDMENT AND WAIVER.  Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Required Holders; provided that no such action may increase the exercise price of any SPA Warrant or decrease the number of shares or class of stock obtainable upon exercise of any SPA Warrant without the written consent of the Holder.  No such amendment shall be effective to the extent that it applies to less than all of the holders of the SPA Warrants then outstanding.

                    10.     GOVERNING LAW.  This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

                    11.     CONSTRUCTION; HEADINGS.  This Warrant shall be deemed to be jointly drafted by the Company and all the Buyers and shall not be construed against any person as the drafter hereof.  The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.

                    12.     DISPUTE RESOLUTION.  In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two Business Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder.  If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and
approved by the Holder  or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent,

- 14 -

outside accountant.  The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten Business Days from the time it receives the disputed determinations or calculations.  Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.  

                    13.     REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF.  The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder right to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.  The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in
addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

                    14.     TRANSFER.     (a)This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company, except as may otherwise be required by Section 2(f) of the Securities Purchase Agreement.  Each Person to whom this Warrant is sold, assigned or transferred by the Holder shall provide to the Company true and accurate information as to such Person comparable to that contained in columns (1), (2) and (7) of the Schedule of Buyers attached to the Securities Purchase Agreement and as to the jurisdiction of residence of such Person.

                                        (b)     The Company shall be entitled to treat the registered Holder of this Warrant as the absolute owner hereof and shall incur no liability for the issuance of Common Stock or for other action taken hereunder in good faith based upon such ownership until such time as a written assignment of this Warrant is effected by such registered owner, which assignment has been delivered to the Company and satisfies the requirements of Sections 7(a) and 14(a) hereof.

                    15.     CERTAIN DEFINITIONS.  For purposes of this Warrant, the following terms shall have the following meanings:

                                        (a)     “Bloomberg” means Bloomberg Financial Markets.

                                        (b)     “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.

                                        (c)     “Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing

- 15 -

trade price, as the case may be, then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York Time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC
(formerly the National Quotation Bureau, Inc.).  If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.  If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12.  All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

                                        (d)     “Common Stock” means (i) the Company’s shares of Common Stock, par value $0.01 per share, and (ii) any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock.

                                        (e)     “Common Stock Deemed Outstanding” means, at any given time, the number of shares of Common Stock actually outstanding at such time, plus the number of shares of Common Stock deemed to be outstanding pursuant to Sections 2(a)(i) and 2(a)(ii) hereof regardless of whether the Options or Convertible Securities are actually exercisable at such time, but excluding any shares of Common Stock owned or held by or for the account of the Company or issuable upon conversion and exercise, as applicable, of the SPA Securities and the Warrants.

                                        (f)     “Convertible Securities” means any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.

                                        (g)     “Eligible Market” means the Principal Market, The New York Stock Exchange, Inc., the American Stock Exchange or The Nasdaq Capital Market.

                                        (h)     “Expiration Date” means the third anniversary of the Issuance Date  or, if such date falls on a day other than a Business Day or on which trading does not take place on the Principal Market (a “Holiday”), the next date that is not a Holiday.

                                        (i)     “Fundamental Transaction” means that the Company shall, directly or indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, (iii) allow another Person to make a purchase, tender or exchange offer that is

- 16 -

accepted by the holders of more than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer) or (iv) consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination), or (iv) reorganize, recapitalize or reclassify its Common Stock.

                                        (j)     “Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

                                        (k)     “Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

                                        (l)     “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

                                        (m)     “Principal Market” means the Nasdaq National Market.

                                        (n)     “Registration Rights Agreement” means that certain registration rights agreement by and among the Company and the Buyers.

                                        (o)     “Required Holders” means the holders of the SPA Warrants representing at least a majority of shares of Common Stock underlying the SPA Warrants then outstanding.

                                        (p)      “Securities Purchase Agreement” means that certain Securities Purchase Agreement, dated as of March 20, 2005 (the “Subscription Date”), by and among the Company and the investors (the “Buyers”) referred to therein as amended by the Exchange Agreement.

                                        (q)      “SPA Securities” means the Notes issued pursuant to the Securities Purchase Agreement.

                                        (r)     “Successor Entity” means the Person (or, if so elected by the Required Holders, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered into.

- 17 -

                                        (s)     “XEL Notes” means the convertible promissory notes in the original aggregate principal amount of $10,480,000 due February 5, 2006 issued in connection with the acquisition by the Company of XEL Communications, Inc. and having an outstanding principal balance in the aggregate not in excess of $2,900,000 as of the Subscription Date as amended by the XEL Amendment (as defined in the Exchange Agreement); provided, however, that such notes shall not be amended, restated, renewed, refunded, refinanced or otherwise extended and the outstanding principal balance shall not be increased after the Subscription Date without the consent of the Required Holders.

[Signature Page Follows]

- 18 -

          IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.

	
  
 
  	
  
VERILINK CORPORATION
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
By:
  	
  
 
  
	
  
 
  	
  
 
  	
  

  
	
  
 
  	
  
Name:
  	
  
 
  
	
  
 
  	
  
Title:
  	
  
 
  

EXHIBIT A

SERIES B EXERCISE NOTICE

TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS
 WARRANT TO PURCHASE COMMON STOCK

VERILINK CORPORATION

          The undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Warrant Shares”) of Verilink Corporation, a Delaware corporation (the “Company”), evidenced by the attached Warrant to Purchase Common Stock (the “Warrant”).  Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

          1.  Form of Exercise Price.  The Holder intends that payment of the Exercise Price shall be made as:

                    ____________ a “Cash Exercise” with respect to _________________ Warrant Shares;

                                                 and/or

                    ____________ a “Cashless Exercise” with respect to _______________ Warrant Shares.

          2.  Payment of Exercise Price.  In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in accordance with the terms of the Warrant.

          3.  Delivery of Warrant Shares.  The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of the Warrant.

          4.  The undersigned confirms that the Warrant Shares have been sold in compliance with the applicable Registration Statement (as defined in the Registration Rights Agreement) relative to the registration for resale of such Warrant Shares.

                    Yes ______                    No_______

Notwithstanding anything to the contrary contained herein, this Exercise Notice shall constitute a representation by the undersigned that, after giving effect to the transactions contemplated hereby, the undersigned (together with its affiliates) will not have beneficial ownership (together with the beneficial ownership of such Person’s affiliates) of a number of shares of Common Stock which exceeds the Maximum Percentage.

Date: _______________ __, ______

	
  
 
  	
  

  	
  
 
  
	
  
 
  	
  
Name of Registered Holder
  	
  
 
  

 

	
  
By:
  	
  
 
  	
  
 
  
	
  
 
  	
  

  	
  
 
  
	
  
Name:
  	
  
 
  	
  
 
  
	
  
Title:
  	
  
 
  	
  
 
  

ACKNOWLEDGMENT

          The Company hereby acknowledges this Exercise Notice and hereby directs American Stock Transfer & Trust Company to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated March 21, 2005 and March 9, 2006 from the Company and acknowledged and agreed to by American Stock Transfer & Trust Company.

	
   
  	
  VERILINK CORPORATION
  
	
   
  	
   
  	
   
  
	
   
  	
  By:
  	
   
  
	
   
  	
   
  	
  

  
	
   
  	
  Name:
  	
   
  
	
   
  	
  Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]